Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EMP505
- Development stage
- Preclinical
- Lead developer
- Empiriko
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
EMP505 is a research-stage antibody-drug conjugate (ADC) developed by Empiriko for the treatment of ovarian cancer. It targets folate receptor alpha (FRα), a cell-surface protein highly expressed in various solid tumors, particularly ovarian cancer. The drug is built on Empiriko's RCV™ (Radiolabeled Carrier Vehicle) platform, enabling a theranostic approach where the therapeutic ADC can be paired with a diagnostic imaging agent (EMP502-Dx) to identify patients most likely to respond. EMP505 is designed to deliver a cytotoxic payload directly to FRα-expressing malignant cells, thereby increasing therapeutic efficacy and reducing off-target effects.
Beyond the preview
Go deeper on EMP505.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EMP505.